Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia

Research site

Italy Via Giuseppe Ciotti N. 154, 25018 Montichiari, Italy

1 trial recruiting
Multiple sclerosis · Chronic kidney disease · Arteriosclerosis
Adult patients

About Specializations

Azienda Socio Sanitaria Territoriale Degli Spedali Civili Di Brescia in Montichiari, Italy specialises in clinical trials of conditions such as Multiple sclerosis, Chronic kidney disease, Arteriosclerosis, Type 2 diabetes mellitus, and other specialisations. This site conducts important research.

Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Site location

Via Giuseppe Ciotti N. 15425018 MontichiariItaly

Open in maps ↗

Recruiting now: 1 trial
Conditions studied: 9

More sites in Montichiari Italy

Recruiting now

Ongoing trials

Clinical trials currently enrolling participants at this site.

Quick filters

8 clinical trials

Multiple sclerosis

Recruiting

A study to compare the effectiveness and safety of subcutaneous frexalimab versus intravenous frexalimab in adults with multiple sclerosis

InvestigationalNo placebo

A study to compare the effectiveness and safety of subcutaneous frexalimab versus intravenous frexalimab in adults with multiple sclerosis

InvestigationalNo placebo

Italy

Participants:18–64 years
Substances:Frexalimab
Sponsor:Sanofi-Aventis Recherche & Developpement

Contact Research Centre

Chronic kidney disease+1

Not recruiting

A study of ziltivekimab compared to placebo in people with heart and blood vessel disease, chronic kidney disease and inflammation

Investigational

A study of ziltivekimab compared to placebo in people with heart and blood vessel disease, chronic kidney disease and inflammation

Investigational

Italy

Participants:18–64 years · 65+ years
Substances:Ziltivekimab
Sponsor:Novo Nordisk A/S

Contact Research Centre

Type 2 diabetes mellitus+1

Not recruiting

Study comparing semaglutide with insulin glargine in overweight adults with type 2 diabetes: effectiveness of combined treatment versus insulin alone

Registered drugNo placebo

Study comparing semaglutide with insulin glargine in overweight adults with type 2 diabetes: effectiveness of combined treatment versus insulin alone

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Insulin Glargine
Sponsor:Novo Nordisk A/S

Contact Research Centre

Relapsing-remitting multiple sclerosis

Not recruiting

Study on the Effects of Obexelimab for Patients with Relapsing Multiple Sclerosis

Investigational

Study on the Effects of Obexelimab for Patients with Relapsing Multiple Sclerosis

Investigational

Italy

Participants:18–64 years
Substances:Obexelimab
Sponsor:Zenas Biopharma (USA) LLC

Contact Research Centre

Diffuse large B-cell lymphoma

Not recruiting

Study Comparing Loncastuximab Tesirine and Rituximab with Standard Treatment for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Registered drugNo placebo

Study Comparing Loncastuximab Tesirine and Rituximab with Standard Treatment for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

Registered drugNo placebo

Italy

Participants:18–64 years · 65+ years
Substances:Dexamethasone
Sponsor:ADC Therapeutics SA

Contact Research Centre

Relapsing multiple sclerosis

Not recruiting

Study on the Effectiveness and Safety of Remibrutinib Compared to Teriflunomide for Patients with Relapsing Multiple Sclerosis

Registered drug

Study on the Effectiveness and Safety of Remibrutinib Compared to Teriflunomide for Patients with Relapsing Multiple Sclerosis

Registered drug

Italy

Participants:18–64 years
Substances:Charcoal, Activated
Sponsor:Novartis Pharma AG

Contact Research Centre

Multiple sclerosis relapse

Not recruiting

Study on the Effectiveness and Tolerability of Ofatumumab Compared to a Drug Combination for Patients with Newly Diagnosed Relapsing Multiple Sclerosis

Registered drugNo placebo

Study on the Effectiveness and Tolerability of Ofatumumab Compared to a Drug Combination for Patients with Newly Diagnosed Relapsing Multiple Sclerosis

Registered drugNo placebo

Italy

Participants:18–64 years
Substances:Dimethyl Fumarate
Sponsor:Novartis Pharma AG

Contact Research Centre

Multiple sclerosis

Not recruiting

Study on Long-Term Safety and Efficacy of Ocrelizumab for Patients with Multiple Sclerosis

Registered drugNo placebo

Study on Long-Term Safety and Efficacy of Ocrelizumab for Patients with Multiple Sclerosis

Registered drugNo placebo

Italy

Participants:18–64 years
Substances:Ocrelizumab
Sponsor:F. Hoffmann-La Roche AG

Contact Research Centre

Is this your site?

Join our network of research sites

Get verified: confirm your contact details and recruitment status with us, appear first on the pages of your trials and receive patient requests directly.

See the offer for sites